CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $971,346 | +46.6% | 21,400 | +81.4% | 0.01% | +66.7% |
| Q2 2023 | $662,452 | +97.9% | 11,800 | +59.5% | 0.01% | +100.0% |
| Q1 2023 | $334,702 | -62.3% | 7,400 | -45.6% | 0.00% | -70.0% |
| Q3 2022 | $888,760 | -22.2% | 13,600 | -25.3% | 0.01% | -9.1% |
| Q1 2022 | $1,142,000 | -11.9% | 18,200 | +6.4% | 0.01% | +22.2% |
| Q4 2021 | $1,296,000 | -24.3% | 17,100 | +11.8% | 0.01% | -50.0% |
| Q3 2021 | $1,713,000 | +65.3% | 15,300 | +139.1% | 0.02% | +80.0% |
| Q2 2021 | $1,036,000 | +21.5% | 6,400 | -8.6% | 0.01% | +25.0% |
| Q1 2021 | $853,000 | +23.8% | 7,000 | +55.6% | 0.01% | +14.3% |
| Q4 2020 | $689,000 | -45.4% | 4,500 | -70.2% | 0.01% | -50.0% |
| Q3 2020 | $1,263,000 | +20.2% | 15,100 | +5.6% | 0.01% | +16.7% |
| Q2 2020 | $1,051,000 | +78.4% | 14,300 | +2.9% | 0.01% | +50.0% |
| Q1 2020 | $589,000 | – | 13,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |